News from Patheon, AmerisourceBergen and Premier Research – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags: Management occupations, Drug discovery

Outsourcing-Pharma presents its weekly round-up of the latest chops and changes within the pharmaceutical jobs market, with news from Patheon, AmerisourceBergen and Premier Research.

Paul Levy​ has become the new chairman of Patheon.

Levy, who first joined the CDMO's (contract development and manufacturing organisation) board in 2007, replaces Ramsey Frank​, who resigned as chairman and director.

Prior to taking on his new role, Levy was managing director for private equity investment firm JLL Partners, which tried to buy Patheon in in 2009. He also founded JLL in 1988.

Elsevier ​has named Jay Katzen ​as managing director for its clinical decision support group.

Formerly the managing director of the medical information services bod’s academic and government markets unit, Katzen was previously responsible for delivering the SciVerse platform for scientific search and discovery.

In his new role, he will take charge of all CDS operations and strategy, including product development, marketing, M&A (mergers and acquisitions) and sales.

Michael Hansen, CEO of Elsevier said: “I'm looking forward to having Jay bring that experience to create new solutions that allow healthcare professionals to provide better, safer and faster care and we are pleased to have Jay lead our efforts.”

AmerisourceBergen’s ​executive VP and chief financial officer Michael DiCandilo​ has quit the firm to “pursue other interests”.

"Mike departs the Company with an impeccable record of service over his 21 years, including the past ten as our Chief Financial Officer,"​ said Steven Collis, president and CEO

The firm’s VP and corporate controller Tim Guttman​ will serve as interim CFO in his stead. In a statement, a spokesperson said the firm is now hunting for a new permanent industry expert for the role.

As previously stated, the company still expects diluted earnings per share in fiscal year 2012 to be in the range of $2.74 to $2.84.

Premier Research Group​ has appointed Sean Russell​ as VP of marketing.

Prior to joining the firm, Russell had a 16-year career at Quintiles, where he created a global marketing service focused on quantitative, integrated marketing programmes to secure and retain customers.

In his new position, he will lead the global development of marketing for the firm.

Ludo Reynders, CEO, said: “As Premier Research continues to seek ways of meeting increased customer demand, we have brought Sean on board to ensure that customers understand our capabilities and seek us out to support their drug development efforts.”

German-based Proteros Biostructures​ has appointed Klaus Hinterding​ as chief scientific officer, and new member of the board.

Before joining Proteros, Hinterding was life cycle leader at Roche, where he implemented an innovative development and commercial strategy for leading late-stage development candidates.

He takes on his new role in time for Proteros’ expansion plans in the drug development arena.

Torsten Neuefeind, founder and CEO said: “Klaus will be responsible for growing the organization that supports our clients as they rely on Proteros to deliver analytical services of crystallography, compound profiling, proteins and increasingly lead compounds, through innovative, integrated structure guided drug discovery collaborations.”

Clinigen​ has drafted in Shaun Chilton ​as chief operating officer of its group’s services division.

In the newly created role, he will take the helm of the incorporation of two operations; clinical supply biz Keats Healthcare and Clinigen GAP, a lifecycle prescription drugs provider.

Prior to joining the team, Chilton was president and managing director at information and services provider KnowledgePoint360 Group.

Related topics: Bio Developments

Related news

Follow us

Products

View more

Webinars